hyaluronan and proteoglycan link protein 3Genealiases: EXLD1 · HsT19883
Q-omics provides the consensus-scored HAPLN3 profile across patient tissues and cancer cell-line models. HAPLN3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HAPLN3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, HAPLN3 protein abundance shows 18,086 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, COAD, and PDAC as cancer lineages where HAPLN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HAPLN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HAPLN3 survival associations across molecular data types. HAPLN3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HAPLN3 RNA expression–survival associations across cancer types. High HAPLN3 expression shows unfavorable associations in KIRP, KIRC and LGG, but favorable associations in SKCM, CESC and SCLC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HAPLN3 RNA expression.
This table summarizes HAPLN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HAPLN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HAPLN3 shows higher tumor expression in COAD, KIRC, HNSC, STAD, LUAD and THCA. The COAD box plot shows higher HAPLN3 RNA expression in tumor versus normal tissue (log2 FC = +2.034, t-test p < 0.001).
This table shows molecular features associated with HAPLN3 in patient tissues and cancer cell lines. In patient samples, HAPLN3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HAPLN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
